Title : A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Pub. Date : 2006 Nov 15

PMID : 16857985






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. lestaurtinib fms related receptor tyrosine kinase 3 Homo sapiens
2 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. lestaurtinib fms related receptor tyrosine kinase 3 Homo sapiens
3 We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. lestaurtinib fms related receptor tyrosine kinase 3 Homo sapiens
4 We undertook a phase 2 trial of the FLT3-selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. lestaurtinib fms related receptor tyrosine kinase 3 Homo sapiens